AB-423 |
Katalog-Nr.GC19014 |
AB-423 ist ein Inhibitor der HBV-Kapsid-Assemblierung und hemmt wirksam die HBV-Replikation mit EC50/EC90 von 0,08-0,27 μM/0,33-1,32 μM in Zellen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1572510-80-5
Sample solution is provided at 25 µL, 10mM.
AB-423 is an inhibitor of HBV capsid assembly, and potent inhibits HBV replication with EC50/EC90 of 0.08-0.27 uM/0.33-1.32 uM in cells.
AB-423 is an inhibitor of HBV capsid assembly. AB-423 shows inhibitory effect on rcDNA production in AML12-HBV10 and HepDE19 cells with EC50s of ∼0.260 uM. AB-423 also suppresses cccDNA formation-dependent HBeAg production in the HepBHAe82 assay with an EC50 of 0.267 uM and inhibits HBV DNA levels in culture supernatants of HepG 2.2.15 cells with an EC50 of 0.134 uM. However, AB-423 has no cytotoxicity in any of the three cell lines[1].
AB-423 (30 and 100 mg/kg, p.o. bid) blocks HBV replication in a mouse model of HBV. AB-423 (100 mg/kg, p.o. bid) with entecavir (ETV, 100 ng/mg, qd, p.o.) or 0.1 mg/kg dose of ARB-1467 potently inhibits serum HBV DNA in an HDI model of HBV in immunodeficient NOD-SCID mice[1].
References:
[1]. Mani N, et al. Preclinical profile of AB-423, an inhibitor of Hepatitis B virus pgRNA encapsidation. Antimicrob Agents Chemother. 2018 Mar 19.
Average Rating: 5
(Based on Reviews and 28 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *